Mark D. Tyson II, M.D., MPH, discusses how recent updates to clinical guidelines now cautiously embrace bladder-sparing gene therapies like nadofaragene for patients with BCG-unresponsive non-muscle invasive bladder cancer, exploring the evolving treatment landscape, operational challenges, and real-world implementation strategies that are shifting the field toward more personalized, less invasive approaches while maintaining oncologic efficacy.
Edward Lain, M.D., MBA, discusses how vitiligo is a complex autoimmune condition involving melanocyte destruction through both innate and adaptive immune mechanisms, presenting as either segmental or nonsegmental forms with significant psychosocial impacts, and requiring multidisciplinary care including dermatologic treatment with FDA-approved ruxolitinib cream, systemic therapies and light-based treatments while addressing comorbidities like thyroid disease and providing psychological support for patients dealing with the visible nature of this unpredictable condition.
nna Podolanczuk, MD, MS, discusses how understanding the risk factors, early diagnosis, and emerging treatment options for interstitial pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) can significantly improve patient outcomes and address critical gaps in current clinical care.
Jeffrey Dunn, PharmD, MBA, discusses how assisted reproductive technologies (ART) are evaluated, implemented and improved through comparison trials, comprehensive program design and consideration of social determinants of health.
Lucy van de Wiel, PhD, examines the key background information on infertility, such as epidemiology, diagnosis, and the psychosocial burden placed on patients.
Kenan Omurtag, MD, explores different treatment options for patients struggling with infertility; assisted reproductive technologies are compared and contrasted.
A panel of experts explore the patient journey and unmet needs of patients with treatment resistant depression (TRD), outline treatment strategies for TRD outside of oral antidepressants/antipsychotics and explore strategies to support access to these alternative therapies through improved billing/coding strategies.
Estay Greene, PharmD, MBA, provides insights on ways to improve the care of patients with diabetes, with a focus on data surrounding the use of continuous glucose monitors.
In this in-depth analysis, we investigate the untapped potential within payer-provider collaborations to enhance coordination in fertility treatment. Delving into strategic approaches that expedite the initiation of fertility treatments, we pinpoint critical areas where patients encounter obstacles, paving the way for optimized care delivery and improved patient outcomes.
A panel of experts discuss several topics including an overview of vitiligo, an evaluation of therapy options for vitiligo, and payer perspectives for the management of vitiligo.
Experts discuss the evolving landscape of hemophilia A treatment from medical and specialty pharmacy perspectives.
Medical experts discuss the benefits and barriers of implementing prescription digital therapeutics.
Jennifer Roggenbuck, MS, CGC, navigates the testing, diagnosis, and management of patients with ALS.
Key opinion leaders discuss the landscape surrounding multi-drug resistant (MDR) therapies for patients with HIV.
Three experts discuss the impact of digital therapeutics (DTx) and prescription digital therapeutics (PDTs) as behavioral health therapy, from benefits to the treatment space to potential improvements and unmet needs.
Two experts discuss uterine fibroids and treating the disease as both a provider and payer.
Discussion on how to address barriers and disparities as obstacles to the use of PrEP, with a focus on increased understanding and education around US Preventive Services Task Force PrEP guidelines and Affordable Care Act Part 47 for payers and providers.
A payer and community physician raise attention to limitations surrounding measures for screening and treating atopic dermatitis.
A discussion on the clinical and managed care considerations of wet AMD treatment, including the varying approaches to disease management.
Multiple sclerosis (MS) is a chronic disease that involves demyelination of plaque throughout the white and gray matter of the central nervous system. The early stages of MS are usually marked by a relapsing-remitting course of neurological deficits, which progress toward continuous, permanent dysfunction and disability. Of those with a diagnosis of MS, 74% are women.
A multi-stakeholder panel discussion featuring insight on the use of prescription digital therapeutics as tools when managing behavior-driven conditions.
As the American population ages, chronic conditions are becoming an increasing challenge for payers. In addition to conditions such as cardiovascular disease and diabetes, eye disease is also prevalent among aging adults.
